Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 38 for:    Recruiting Studies | Antidepressants | United States
Previous Study | Return to List | Next Study

Does Antidepressant Use Blunt Adaptations to Exercise?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03934723
Recruitment Status : Recruiting
First Posted : May 2, 2019
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Matthew Schubert, California State University, San Marcos

Brief Summary:
Nearly one out of ten US adults over the age of 18 currently takes antidepressant medication, which can also treat other conditions such as anxiety. Combining pharmaceutical treatment with exercise may yield even greater benefits than using drugs alone, and this is commonly prescribed for depression. However, little is known about the drug-exercise interactions and their influence on metabolic health. A common side effect of antidepressant use is weight gain, particularly abdominal (visceral) fat, which is highly detrimental to overall health. Exercise is a well-known counter to abdominal fat accumulation. The aim of the proposed study is to compare the efficacy of 6 weeks of exercise training to reduce abdominal fat in healthy overweight/obese adults either taking or not taking antidepressant medication. Twenty-four inactive overweight/obese, but otherwise healthy, adults will complete 6 weeks of an exercise training intervention consisting of three days of aerobic exercise training per week. Participants will either not be taking antidepressant medication or will have been on their medication for at least 1 year. The primary outcome will be abdominal fat determined by waist circumference and dual x-ray absorptiometry, which is considered one of the optimal methods for assessment of abdominal fat.

Condition or disease Intervention/treatment Phase
Depression Depressive Disorder Metabolic Syndrome Behavioral: Exercise Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Do Antidepressant Medications Blunt Responses to Exercise Training in Overweight and Obese Individuals?
Actual Study Start Date : June 15, 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Control
This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms.
Behavioral: Exercise
The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.

Experimental: Antidpressants
This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year.
Behavioral: Exercise
The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.




Primary Outcome Measures :
  1. Visceral adipose tissue (VAT) [ Time Frame: Change from baseline after 6 weeks. ]
    VAT assessed by dual-energy X-ray absorptiometry (DXA)

  2. Waist circumference [ Time Frame: Change from baseline after 6 weeks. ]
    Waist circumference is a proxy of VAT


Secondary Outcome Measures :
  1. Aerobic fitness [ Time Frame: Change from baseline after 6 weeks. ]
    Fitness assessed via a maximal treadmill exercise test

  2. Blood pressure [ Time Frame: Change from baseline after 6 weeks. ]
    Resting blood pressure assessed with an oscillatory blood pressure monitor

  3. Blood glucose [ Time Frame: Change from baseline after 6 weeks. ]
    Fasting capillary glucose sample

  4. Blood lipid panel [ Time Frame: Change from baseline after 6 weeks. ]
    Fasting capillary blood sample for triglycerides and cholesterol

  5. Body mass [ Time Frame: Change from baseline after 6 weeks. ]
    Body mass measured on a scale

  6. Fat mass [ Time Frame: Change from baseline after 6 weeks. ]
    Total and segmental body fat mass measured by DXA

  7. Lean mass [ Time Frame: Change from baseline after 6 weeks. ]
    Total and segmental lean mass measured by DXA

  8. Dietary intake [ Time Frame: Change from baseline after 6 weeks. ]
    Food logs recorded over two week days and one weekend day

  9. Physical activity [ Time Frame: Change from baseline after 6 weeks. ]
    Free-living physical activity assessed over 7 days via combined heart-rate and accelerometry

  10. Depression symptoms [ Time Frame: Change from baseline after 6 weeks. ]
    Symptoms of depression assessed with Beck's Depression Inventory (BDI). The BDI is a 21-item questionnaire that measures total depressive symptoms. Individual item scores range from 0-3. Individual items are then summed to provide a total score, ranging from 0 to 63.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants will be English language speakers
  • Male or females between the ages of 18-40.
  • All genders and ethnicities.
  • Healthy as assessed by a health history questionnaire (no diagnosed physical diseases or conditions preventing participation in exercise).
  • Individuals on antidepressants will be recruited if they are consuming selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) only. Participants will send prescription information after consent has been provided as part of the screening process, including the dose and frequency of medication.
  • A body mass index (BMI) of 25 or greater is required for inclusion.

Exclusion Criteria:

  • Inability to complete moderate-vigorous exercise.
  • Taking first generation antidepressant medications or other medications such as monoamine oxidase inhibitors (MAOI).
  • Other medications, such as medications for attention-deficit hyper-activity disorder or metabolism
  • Undiagnosed depression that may be unveiled during the screening process.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03934723


Contacts
Layout table for location contacts
Contact: Dean of Graduate Studies and Research (760) 750-4066 OGSR@csusm.edu

Locations
Layout table for location information
United States, California
California State University San Marcos Recruiting
San Marcos, California, United States, 92078
Contact: Matthew M Schubert, Ph.D.    760-750-7362    mschubert@csusm.edu   
Principal Investigator: Matthew M Schubert, Ph.D.         
Sponsors and Collaborators
California State University, San Marcos

Layout table for additonal information
Responsible Party: Matthew Schubert, Assistant Professor of Kinesiology, California State University, San Marcos
ClinicalTrials.gov Identifier: NCT03934723     History of Changes
Other Study ID Numbers: 1423972-1
First Posted: May 2, 2019    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Matthew Schubert, California State University, San Marcos:
Exercise
Antidepressants
Visceral fat
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Depressive Disorder
Mood Disorders
Mental Disorders
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Antidepressive Agents
Psychotropic Drugs